URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Matthew Gall Biography and Net Worth

CFO of iTeos Therapeutics

Matthew joined iTeos from Sarepta Therapeutics, Inc. in June 2020 where he was the Senior Vice President of Corporate Development and Treasurer and where he led the Company’s recent partnering process with Roche, resulting in a multibillion dollar collaboration agreement and raised over $2billion from capital markets. During his 15 year career in biotech financial management and corporate development, Matthew also worked at Celgene and Gilead Sciences. Matthew has an MBA from the University of Chicago Booth School of Business.

What is Matthew Gall's net worth?: The estimated net worth of Matthew Gall is at least $485,483.18 as of November 19th, 2024. Mr. Gall owns 65,429 shares of iTeos Therapeutics stock worth more than $485,483 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Gall may own. Additionally, Mr. Gall receives a salary of $648,000.00 as CFO at iTeos Therapeutics. Learn More about Matthew Gall's net worth.
How old is Matthew Gall?: Mr. Gall is currently 47 years old. There are 4 older executives and no younger executives at iTeos Therapeutics. The oldest executive at iTeos Therapeutics is Dr. Michel Detheux Ph.D., President, CEO & Director, who is 57 years old. Learn More on Matthew Gall's age.
What is Matthew Gall's salary?: As the CFO of iTeos Therapeutics, Inc., Mr. Gall earns $648,000.00 per year. There are 2 executives that earn more than Mr. Gall. The highest earning executive at iTeos Therapeutics is Dr. Michel Detheux Ph.D., President, CEO & Director, who commands a salary of $1,040,000.00 per year. Learn More on Matthew Gall's salary.
How do I contact Matthew Gall?: The corporate mailing address for Mr. Gall and other iTeos Therapeutics executives is , , . iTeos Therapeutics can also be reached via phone at 339-217-0161 and via email at [email protected]. Learn More on Matthew Gall's contact information.
Has Matthew Gall been buying or selling shares of iTeos Therapeutics?: During the last quarter, Matthew Gall has bought $38,650.00 in iTeos Therapeutics stock. Most recently, on Tuesday, November 19th, Matthew Gall bought 5,000 shares of iTeos Therapeutics stock. The stock was acquired at an average cost of $7.73 per share, with a total value of $38,650.00. Following the completion of the transaction, the chief financial officer now directly owns 65,429 shares of the company's stock, valued at $505,766.17. Learn More on Matthew Gall's trading history.
Who are iTeos Therapeutics' active insiders?: iTeos Therapeutics' insider roster includes Detlev Biniszkiewicz (Director), Michel Detheux (CEO), Ansbert Gadicke (Major Shareholder), Matthew Gall (CFO), David Hallal (Director), Les Korsh (VP), Joanne Lager (Insider), and Yvonne McGrath (VP). Learn More on iTeos Therapeutics' active insiders.
Are insiders buying or selling shares of iTeos Therapeutics?: During the last year, iTeos Therapeutics insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $38,650.00. The most recent insider tranaction occured on November, 19th when CFO Matthew Gall bought 5,000 shares worth more than $38,650.00. Insiders at iTeos Therapeutics own 12.5% of the company. Learn More about insider trades at iTeos Therapeutics.
Information on this page was last updated on 11/19/2024.

Matthew Gall Insider Trading History at iTeos Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/19/2024	Buy	5,000	$7.73	$38,650.00	65,429
10/12/2023	Buy	5,000	$8.37	$41,850.00	19,429
12/27/2021	Sell	5,000	$46.45	$232,250.00
6/16/2021	Buy	5,000	$26.09	$130,450.00	5,000

Matthew Gall Buying and Selling Activity at iTeos Therapeutics

iTeos Therapeutics Company Overview

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $7.42

$7.09

$7.51

50 Day Range

MA: $8.54

$7.22

$9.73

2 Week Range

Now: $7.42

$7.09

$18.75

Volume

2,443,768 shs

Average Volume

452,593 shs

Market Capitalization

$271.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Matthew Gall Biography and Net Worth

What is Matthew Gall's net worth?

How old is Matthew Gall?

What is Matthew Gall's salary?

How do I contact Matthew Gall?

Has Matthew Gall been buying or selling shares of iTeos Therapeutics?

Who are iTeos Therapeutics' active insiders?

Are insiders buying or selling shares of iTeos Therapeutics?